Department of Pathology, University Clinical Hospital, University of Santiago de Compostela, Santiago de Compostela, Spain.
Histol Histopathol. 2012 Aug;27(8):1021-7. doi: 10.14670/HH-27.1021.
the assessment of the human epidermic growth factor receptor 2 (HER2) is currently performed in most laboratories using two techniques: Fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC), and novel methodology is being investigated continuously in the assessment of HER2, such as SISH, CISH, DNA chips, ELISA or real time PCR to make assessment easier, faster or more accurate. RNA-ISH (RNA in Situ Hybridisation) is a new technique designed to detect mRNA expression levels, conducted by light microscope without the need for counting or grading systems in a total processing time of 4 hours. This study aims to determine if RNA-ISH is a viable and effective technique and a possible alternative to the currently used techniques by analysing and comparing genetic amplification (FISH) and protein levels (IHC) with mRNA over-expression (RNA-ISH) in 141 cases of breast cancer.
This study demonstrated a 96.5% concordance between over-expression of HER2 as determined by RNA-ISH and gene amplification as determined by FISH. The relationship between RNA-ISH-evaluated and IHC-evaluated over-expression was equally well reflected with a 95.2% concordance. Importantly, a considerable reduction in processing and evaluation time was achieved of only 4 hours.
We conclude that the probe developed for RNA-ISH represents a viable, effective possible alternative to FISH and IHC for analysing HER2 status in primary breast tumours.
目前大多数实验室采用两种技术来评估人表皮生长因子受体 2（HER2）：荧光原位杂交（FISH）和免疫组织化学（IHC），并且不断在探索新的方法来评估 HER2，如 SISH、CISH、DNA 芯片、ELISA 或实时 PCR，以使其评估更简单、更快或更准确。RNA-ISH（RNA 原位杂交）是一种新的技术，旨在检测 mRNA 表达水平，通过光学显微镜进行，无需计数或分级系统，总处理时间为 4 小时。本研究旨在通过分析和比较 141 例乳腺癌的基因扩增（FISH）和蛋白水平（IHC）与 mRNA 过表达（RNA-ISH），确定 RNA-ISH 是否是一种可行且有效的技术，是否可以替代目前使用的技术。
本研究显示，通过 RNA-ISH 确定的 HER2 过表达与通过 FISH 确定的基因扩增之间具有 96.5%的一致性。RNA-ISH 评估的与 IHC 评估的过表达之间的关系同样具有 95.2%的一致性。重要的是，处理和评估时间大大缩短，仅为 4 小时。
我们得出结论，针对 RNA-ISH 开发的探针代表了一种可行、有效的替代 FISH 和 IHC 的方法，可用于分析原发性乳腺癌中的 HER2 状态。
